IV-01 Stefaan Rossenu Population Pharmacokinetics of MK-3475, a human Anti-PD-1 Monoclonal Antibody in patients with progressive locally advanced or metastatic carcinoma, melanoma, and non-small cell lung carcinoma Thursday 15:15-16:40 |
IV-02 Tarjinder Sahota Interactive population PK/PD model simulations in R Thursday 15:15-16:40 |
IV-03 Maria Luisa Sardu Steady-state equivalence of drug- and biomarker driven models in tumor growth experiments Thursday 15:15-16:40 |
IV-04 Andre Schäftlein Population modeling of the relationship between the pharmacokinetics of the oral thrombin inhibitor dabigatran etexilate and coagulation biomarkers in patients with non-valvular atrial fibrillation from the RE-LY trial Thursday 15:15-16:40 |
IV-05 Emilie Schindler PKPD-Modeling of individual lesion maximal standardized uptake value (SUV) in Gastro-Intestinal Stromal Tumors (GIST) patients treated with sunitinib Thursday 15:15-16:40 |
IV-06 Jan-Frederik Schlender Development of a whole-body PBPK approach to assess the pharmacokinetics of xenobiotics in elderly individuals Thursday 15:15-16:40 |
IV-07 Stephan Schmidt Evaluation of changes in oral drug absorption in preterm neonates for BCS class I and II compounds Thursday 15:15-16:40 |
IV-08 Siti Maisharah Sheikh Ghadzi Are insulin measurements needed in glucose provocation studies? : Comparison of study power using Monte-Carlo Mapped Power (MCMP) method Thursday 15:15-16:40 |
IV-09 Shinji Shimizu PBPK modeling of CNS distribution for risperidone and its active metabolite, paliperidone Thursday 15:15-16:40 |
IV-10 Kwang-Hee Shin A population pharmacokinetic/pharmacodynamic approaches of a peglyated granulocyte-colony stimulating factor (G-CSF) in healthy Korean Thursday 15:15-16:40 |
IV-11 Satoshi Shoji Evaluation of information of prior relative to current data in analysis with prior Thursday 15:15-16:40 |
IV-12 Nelleke Snelder A new model-based approach to compare toxicity of a series of compounds based on their categorical toxicity scores Thursday 15:15-16:40 |
IV-13 Kabir Soeny A Novel Algorithm for Optimizing Dose Regimens and Fixed Dose Combination Ratios Thursday 15:15-16:40 |
IV-14 Mijeong Son Population Pharmacokinetic-Pharmacodynamic modeling of Olemsartan in Healthy Korean Volunteers Thursday 15:15-16:40 |
IV-15 Konstantina Soulele A population pharmacokinetic study of fluticasone/salmeterol in healthy subjects using two different dry powder inhalers Thursday 15:15-16:40 |
IV-16 Christine Staatz A survey of intravenous tobramycin monitoring and dosage adjustment practice in cystic fibrosis patients in Australia and the United Kingdom Thursday 15:15-16:40 |
IV-17 Elisabet Størset Evaluation of dosing strategies to achieve targeted tacrolimus exposure after adult kidney transplantation Thursday 15:15-16:40 |
IV-18 Fran Stringer Evaluating the clinical influence of UGT2B15 genotype on the pharmacodynamic response of the PPAR agonist, sipoglitazar Thursday 15:15-16:40 |
IV-19 Mark Stroh Meta-analysis of Published Efficacy and Safety Data for Docetaxel in Second-Line Treatment of Patients with Advanced Non-Small-Cell Lung Cancer Thursday 15:15-16:40 |
IV-20 Eric Strömberg Design evaluation using a bootstrapped Monte Carlo variance-covariance matrix. Thursday 15:15-16:40 |
IV-21 Kim Stuyckens Modelling and simulation approach to optimize the pharmacological activity during a Phase 1 study of JNJ-42756493, a selective and potent FGFR 1, 2 ,3 and 4 inhibitor. Thursday 15:15-16:40 |
IV-22 Siddharth Sukumaran Development of a Mechanism-based pharmacokinetic model for MMAE conjugated ADCs Thursday 15:15-16:40 |
IV-23 Ahmed Suleiman A survival modeling analysis evaluating the use of positron emission tomography with [(18)F]-fluorodeoxyglucose for predicting the prognosis in advanced non-small cell lung cancer patients first-treated with erlotinib Thursday 15:15-16:40 |
IV-24 Amit Taneja Development of a mechanism-based pharmacokinetic-pharmacodynamic model of prolactin response following administration of D2 antagonists in rats Thursday 15:15-16:40 |
IV-25 Paulo Teixeira Population Pharmacokinetic Model of Valproic Acid in Adult Patients: an Update Thursday 15:15-16:40 |
IV-26 Nadia Terranova An energy based model able to describe the effect of anticancer drugs on tumor growth and host body weight Thursday 15:15-16:40 |
IV-27 Adrien Tessier Contribution of nonlinear mixed effects models and penalised regression approaches in pharmacogenetic population studies Thursday 15:15-16:40 |
IV-29 Melanie Titze A semi-mechanistic model to describe the bidirectional interaction between oncolytic reovirus and in vitro tumor growth of U87-glioblastoma cells Thursday 15:15-16:40 |
IV-30 Iñaki F. Trocóniz Population pharmacokinetic/pharmacodynamic modelling of the analgesic and pupillometry effects of axomadol and its O-demethyl metabolite in healthy subjects Thursday 15:15-16:40 |
IV-31 Sebastian Ueckert Accelerating Monte-Carlo Power Studies through Parametric Power Estimation Thursday 15:15-16:40 |
IV-32 Pavan Vajjah Exposure-response relationship of certolizumab pegol in psoriatic arthritis patients and comparison of ACR 20/50/70 response rates in the two dosage regimens Thursday 15:15-16:40 |
IV-33 Elodie Valade Modified renal function in pregnancy: impact on emtricitabine pharmacokinetics Thursday 15:15-16:40 |
IV-34 Pyry Välitalo Evaluation of gentamicin and tobramycin dosing guidelines for neonates; towards model-based dosing Thursday 15:15-16:40 |
IV-35 Sven van Dijkman A PKPD Hidden Markov Model for Lamotrigine in all age groups Thursday 15:15-16:40 |
IV-36 Coen van Hasselt Development of an integrated model-based framework to support clinical development of antibiotics Thursday 15:15-16:40 |
IV-37 Eline van Maanen Integrating tracer kinetic data with absolute protein concentration measurements in a systems pharmacology model. Application to the APP pathway in CMP rhesus monkeys. Thursday 15:15-16:40 |
IV-38 Anne van Rongen Population pharmacokinetics of a single intravenous dose of midazolam in obese, overweight and non-obese adolescents Thursday 15:15-16:40 |
IV-39 Rob van Wijk Challenges in the evaluation of the preclinical dosing rationale for tuberculosis treatment Thursday 15:15-16:40 |
IV-40 Marc Vandemeulebroecke Identifying neuropsychological domains with high information on early signs of cognitive decline: An application of Item Response Theory in the Basel Study on the Elderly Thursday 15:15-16:40 |
IV-41 Nieves Velez de Mendizabal Analysis of Sleep Changes Induced by Citalopram: A Population Approach Thursday 15:15-16:40 |
IV-42 Swantje Völler Age-Dependent Pharmacokinetics of Doxorubicin in Children with Cancer: Results of the EPOC-MS-001 Study Thursday 15:15-16:40 |
IV-43 Chenguang Wang Population pharmacokinetics of paracetamol across the human age-range from (pre)term neonates, infants, children to adults Thursday 15:15-16:40 |
IV-44 Shaonan Wang Exposure-response analysis of Axomadol in patients suffering from hip and/or knee-joint osteoarthritis pain Thursday 15:15-16:40 |
IV-45 Franziska Weber Evaluation of candidate drugs to induce the redundant gene ABCD2 as an alternative treatment option for X-linked adrenoleukodystrophy Thursday 15:15-16:40 |
IV-46 Thierry Wendling Nonlinear mixed-effects modelling of the oral absorption of mavoglurant following administration of an immediate- and a modified-release formulation in healthy subjects Thursday 15:15-16:40 |
IV-47 Sebastian Wicha Adaptive optimal design for the concentration tiers in time-kill curve experiments. Thursday 15:15-16:40 |
IV-48 Pawel Wiczling PK/PD of propofol and fentanyl in patients undergoing abdominal aortic surgery - the influence of cardiac output and drug interactions Thursday 15:15-16:40 |
IV-49 Wenyuan Xiong PK/PD modeling of the c-Met inhibitor MSC2156119J to establish the recommended Phase II dose Thursday 15:15-16:40 |
IV-50 Shuying Yang Probability of Success with Exposure Response Modelling and Clinical Trial Simulation as a Tool to Support Decision Making Thursday 15:15-16:40 |
IV-51 Huixin Yu Integrated mechanism-based pharmacokinetic model for sunitinib and its active metabolite Thursday 15:15-16:40 |
IV-52 Hinojal Zazo Gómez PK/PD modelling and simulation of stavudine nanoparticles in HIV patients Thursday 15:15-16:40 |
IV-53 Stefan Zeiser Whole-Body PBPK Modeling of Tacrolimus in Healthy Volunteers Thursday 15:15-16:40 |
IV-54 Jianping Zhang Pharmacokinetics of eltrombopag in patients with hepatic impairment Thursday 15:15-16:40 |
IV-55 Liping Zhang A Mechanistic Modeling Approach Characterizing the Interaction of Pharmacokinetics and Pharmacodynamics of a Monoclonal Antibody and the Supply/Synthesis of its target in Cynomolgus Monkey Thursday 15:15-16:40 |
IV-56 Simon Zhou Uncertainty and key factors in assessing drug effect in cell-based and xenograft tumor models in rodents Thursday 15:15-16:40 |
IV-57 Li Zhu Population Pharmacokinetic/Pharmacodynamic Models for the Heart Rate Effects of BMS-820836, a Triple Monoamine Reuptake Inhibitor, in a Thorough QT Study Thursday 15:15-16:40 |
IV-58 Morris Muliaditan Population Pharmacokinetic Meta-Analysis of the Antiretroviral Agent Lamivudine in HIV-Infected Children Thursday 15:15-16:40 |
IV-59 Oscar Della Pasqua Population Pharmacokinetic Meta-Analysis of the Antiretroviral Agent Abacavir in HIV-Infected Children Thursday 15:15-16:40 |